Sibeprenlimab Halves uPCR in IgA Nephropathy Trial

Otsuka Reports More Positive Results From Its Phase 3 Trial of Sibeprenlimab

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

ERA 2025: Sibeprenlimab Halves Proteinuria in IgAN in Phase 3 VISIONARY Trial

Prespecified analysis of 320 patients in VISIONARY were presented at ERA 2025 Congress.

Sibeprenlimab Halves uPCR in IgA Nephropathy Trial

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent safety outcomes, interim phase 3 data shows.